Saturday 17 October 2026
Export CRBU’s income statement to Excel — free account
Caribou Biosciences, Inc.
CRBU Healthcare Biotechnology
Caribou Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 million, up 11.7% from fiscal 2024. In the quarter to June 2026, revenue fell 43.8%, EPS grew 58.6% and free cash flow fell 33.2%, each against the same quarter a year earlier.
0.47
0.00
0.00%
Follow CRBU
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 3 | 4 | 2 | 3 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 5.46 | 2.25 | 3.06 | (1.58) | (5.00) |
P/S ratio |
— | 13.15 | 13.15 | 49.78 | 29.02 | 11.92 | 14.37 | 13.31 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | (6.32) | 11.15 | 4.77 | 6.71 | 0.11 | (9.88) |
P/Operating CF |
— | (10.16) | (10.16) | (22.34) | (16.05) | (19.23) | (4.05) | (7.13) |
Beneish M-Score |
— | — | — | (2.05) | (2.16) | (1.80) | (2.02) | (3.93) |
P/B ratio |
— | 0.00 | 0.00 | 1.23 | 1.34 | 1.12 | 0.57 | 1.22 |
Price to Tangible BV |
— | 0.00 | 0.00 | 1.23 | 1.34 | 1.12 | 0.57 | 1.22 |
EV/Sales |
— | 2.98 | 2.98 | 10.62 | 11.14 | 2.39 | (6.60) | 0.82 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.39 | 0.00 |
EV/Operating CF |
— | (2.94) | (2.94) | (3.14) | (1.70) | (0.88) | 0.48 | (0.08) |
EV/FCF |
— | (2.82) | (2.82) | (2.94) | (1.58) | (0.78) | 0.46 | (0.08) |
Quick Ratio |
— | 4.47 | 1.60 | 14.81 | 8.89 | 11.70 | 6.90 | 5.56 |
Current Ratio |
— | 5.66 | 1.96 | 15.15 | 9.25 | 11.97 | 7.16 | 5.71 |
Net Debt/EBITDA |
— | 1.22 | 0.45 | 5.70 | 2.35 | 2.81 | 1.25 | 0.96 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.69 | 0.04 | 0.03 | 0.09 | 0.03 | 0.05 |
Operating CF/Net income |
— | 1.37 | 0.97 | 0.49 | 0.92 | 0.91 | 0.93 | 0.75 |
Capex/Depreciation |
— | (1.18) | (0.34) | (2.05) | (7.82) | 12.90 | 6.09 | (0.54) |
Interest Coverage |
— | (8,576.25) | (1,806.20) | (452.56) | (23.13) | — | — | — |
| — | 293.36% | 429.55% | (36.73%) | (28.87%) | (30.50%) | (47.99%) | (78.97%) | |
| — | 0.00% | (190.36%) | (27.98%) | (24.36%) | (25.33%) | (40.00%) | (60.62%) | |
ROIC |
— | 0.00% | (1,168.00%) | (349.05%) | (124.98%) | (183.29%) | (239.87%) | 0.00% |
Return on Tangible Assets |
— | (45.71%) | (222.50%) | (18.08%) | (40.95%) | (31.04%) | (71.68%) | (117.02%) |
Average Days of Receivables |
— | 251.11 | 113.15 | 252.36 | 63.69 | 25.77 | 76.44 | 64.53 |
Research and Development Expense of Revenue |
— | 408.34% | 278.50% | 544.44% | 593.68% | 325.07% | 1,302.31% | 980.72% |
Selling, General and Administrative Expense of Revenue |
— | 284.35% | 113.74% | 253.41% | 274.49% | 111.56% | 464.85% | 339.76% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 21.32% | 8.11% | 35.93% | 84.59% | 39.88% | 167.16% | 113.63% |
Graham Net Nets |
— | 0.52 | 0.52 | 0.70 | 0.47 | 0.67 | 1.11 | 0.62 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (24.06%) | (24.06%) | (23.49%) | (24.81%) | (26.03%) | (103.77%) | (100.00%) |
Free Cash Flow Yield |
— | (8.04%) | (8.04%) | (7.25%) | (24.24%) | (25.52%) | (99.62%) | (75.66%) |
Revenue per Share |
— | 0.69 | 1.45 | 0.30 | 0.23 | 0.47 | 0.11 | 0.12 |
Operating CF per Share |
— | (3.82) | (3.89) | (1.03) | (1.50) | (1.26) | (1.53) | (1.19) |
Capex per Share |
— | (0.11) | (0.04) | (0.07) | (0.11) | (0.16) | (0.05) | (0.01) |
Free Cash Flow per Share |
— | (3.93) | (3.92) | (1.09) | (1.60) | (1.42) | (1.58) | (1.20) |
Cash per Share |
— | 4.90 | 1.87 | 11.87 | 4.07 | 4.46 | 2.32 | 1.49 |
Shareholders Equity per Share |
— | 0.00 | 2.09 | 12.25 | 4.95 | 4.99 | 2.80 | 1.31 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | 2.09 | 12.25 | 4.95 | 4.99 | 2.80 | 1.31 |
Free Cash Flow |
— | (32.89) | (33.52) | (34.64) | (97.42) | (104.90) | (143.07) | (112.35) |
Working Capital |
— | 46.93 | 11.92 | 365.36 | 232.12 | 310.54 | 188.73 | 119.82 |
Capital Expenditures |
— | (0.88) | (0.31) | (2.12) | (6.45) | (11.61) | (4.87) | (1.36) |
Net Current Asset Value |
— | 57.01 | 6.15 | 336.66 | 187.35 | 275.03 | 159.02 | 92.04 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.40 | 0.00 |
Capex to Sales |
— | 0.15 | 0.02 | 0.22 | 0.47 | 0.34 | 0.49 | 0.12 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.17 | 0.26 | 0.21 | 0.08 | (0.05) | (0.04) | 0.37 |
Cash ROIC |
— | (80.08%) | (99.06%) | (4.54%) | (17.76%) | (15.05%) | (30.93%) | (42.96%) |
Accounts Receivable Turnover |
— | 1.27 | 3.16 | 1.83 | 3.06 | 14.21 | 4.42 | 5.49 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 4.57 | 3.91 | 5.23 | 4.53 | 2.43 | 2.26 | 2.03 |
Average Payables |
— | 2.57 | 2.57 | 3.30 | 2.57 | 2.13 | 2.80 | 4.13 |
Average Assets |
— | 0.00 | 18.02 | 239.20 | 408.06 | 402.99 | 372.76 | 244.34 |
Average Common Equity |
— | (7.99) | (7.99) | 182.19 | 344.35 | 334.64 | 310.68 | 187.56 |
Columns are period end dates